RxDoctor Payments Data

Benjamin Ticho, MD

Ophthalmology · Chicago Ridge, ILNPI 1992782494

Payments from drug & device makers

$38,085in general payments, 2019–2025

Across 221 payments — averaging $172.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon Research LLC$22K
  • Novartis$8K
  • Amgen$2K
  • AbbVie$1K
  • Mallinckrodt Hospital Products Inc.$764
  • Sight Sciences, Inc.$716
  • plus $4K from 25 others

What the payments were for

  • Consulting fees$1,20014%
  • Food & beverage$6,90483%
  • Education$1982%
  • Gifts$320%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$38,085 in reported general payments places this provider in the 90th percentile of 773 ophthalmology providers in Illinois.

See all ophthalmology providers in Illinois

Medicare billing

Part B allowed, 2024
$527,846
Medicare patients
731
Services billed
3,203

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine30$25,657
XiidraLifitegrast20$15,545
LumiganBimatoprost29$13,236
Cyclosporine31$11,556
CombiganBrimonidine Tartrate/Timolol13$7,685
AzoptBrinzolamide17$6,076
Brimonidine Tartrate63$5,085
Travoprost22$4,731
Latanoprost404$3,939
Alphagan PBrimonidine Tartrate13$3,129
Prednisolone Acetate70$2,998
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat110$2,244
Timolol Maleate160$1,733
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha90$971
Ofloxacin68$964

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$1,015$49,70785 claims
Bausch & Lomb Americas Inc.Xiidra$256$15,54520 claims
AlconAzopt$702$6,07617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 773 ophthalmology providers in Illinois.

Other ophthalmology in Chicago Ridge

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →